Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Budesonide + surfactant is a combination therapy used primarily for the prevention and treatment of bronchopulmonary dysplasia (BPD) in premature infants with respiratory distress syndrome (RDS). This therapy involves mixing budesonide (a glucocorticoid) with pulmonary surfactant and administering it intratracheally. The surfactant acts as a vehicle for budesonide, enhancing its solubility and absorption in the lungs. Budesonide provides anti-inflammatory effects while the surfactant reduces surface tension in the lungs. Studies have shown that this combination can decrease the severity of BPD, reduce the need for mechanical ventilation, and lead to earlier hospital discharge compared to surfactant alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on budesonide + surfactant.